Utah
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Utah: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Utah follows the principles established in the Association for Molecular Pathology case, recognizing that natural phenomena and laws of nature cannot be patented. This aligns with the broader interpretation of patentable subject matter under both federal and state law.
In Utah, similar to federal standards, isolated genomic DNA is not patent eligible if it is not markedly different from that found in nature.
The court held that business methods using natural processes could not be patented if they do not introduce a new and useful invention.
The ruling reaffirmed the non-patentability of naturally occurring substances without transformative development.
Utah's approach mirrors the federal standard set by the U.S. Supreme Court in Mayo Collaborative Services v. Prometheus Laboratories, Inc., ensuring that state law does not extend patent eligibility beyond what is permitted federally. Both levels of law emphasize the need for human ingenuity that transforms natural products into patentable inventions.
Understanding the implications of Myriad Genetics on patentability is crucial for the Utah bar exam as it tests candidates' knowledge on intellectual property law, particularly in relation to biotechnology patents.